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A B S T R A C T   
[Background] Facioscapulohumeral muscular dystrophy (FSHD) is an autosomal dominant muscle disease 
characterized by asymmetric involvement of muscles in the face, upper extremity, trunk, and lower extremity 
regions, with variable severity. It was recently reported that restrictive respiratory involvement is more frequent 
and severe than previously recognized, while cardiac dysfunction other than arrhythmia is still considered 
extremely rare in FSHD. [Case report] A 59-year-old man presenting with marked muscle atrophy in the trunk 
and asymmetrical muscle atrophy in the legs was hospitalized because of dyspnea and edema in the face and 
limbs. Shortness of breath with body movement started from approximately 40 years of age. Muscle biopsy 
revealed myopathic change with mild to moderate variation in fiber size. The diagnosis of FSHD was made by 
D4Z4 contraction to three repeats on genetic testing. A pulmonary function test revealed a decline of forced vital 
capacity (FVC) and a preserved FEV1/FVC indicating restrictive ventilatory defect (RVD). Ultrasonic echocar-
diogram (UCG) showed diffuse left ventricular hypokinesis, ventricular septum thickening, pericardial effusion, 
and decreased ejection fraction (LVEF 30%). [Conclusion] Although restrictive ventilatory defect and congestive 
heart failure are uncommon in FSHD, respiratory and cardiac evaluation may be necessary in patients with 
FSHD.   
1. Introduction 
Facioscapulohumeral muscular dystrophy (FSHD) is an autosomal 
dominant myopathy characterized by asymmetric involvement of mus-
cles in the facial, upper extremity, trunk, and lower extremity regions 
with variable severity. In over 95% of patients, deletion of a 3.3 kb 
tandem repeat, D4Z4, on chromosome 4q35 is present (type1 FSHD) [1]. 
It was recently reported that respiratory involvement in FSHD is more 
frequent and severe than previously recognized [2]. However, cardiac 
dysfunction other than arrhythmia is considered extremely rare in FSHD 
[3]. We present a case of type 1 FSHD with restrictive ventilatory defect 
(RVD) and congestive heart failure (CHF). 
Case report. 
A 59-year-old man was admitted to hospital because of dyspnea and 
edema of the extremities and face. At the age of 12, he first noticed 
difficulty in raising his arms, but he was able to work and live inde-
pendently until the age of 50. Shortness of breath with body movement 
started from approximately 40 years of age. At 55 years of age, he 
noticed muscle weakness in his upper arms. Regarding his medical 
history, hypertension had been noted in the past but was not treated. He 
had no smoking habits and was drunk on occasion. There were no 
obvious myopathic cases in his family. He was born to non- 
consanguineous parents. 
On physical examination, the patient was 75.1 kg in weight, 158 cm 
in height, and 30.4 kg/m2 in body mass index (BMI). Blood pressure was 
135/89 mmHg and heart rate was 73 beats/min, with a resting respi-
ratory rate of 18 breaths/min. Edema was observed in the limbs and the 
eyelids. No obvious heart murmurs and no pulmonary crackles were 
heard on auscultation. Asymmetric muscle weakness was observed in 
the left and proximal dominant upper limbs, but the trapezius and del-
toid muscles were hypertrophic. The patient’s grip strength was 16.1 kg 
in the right and 18.3 kg in the left, respectively. Asymmetrical muscle 
weakness was observed in his lower limbs and gluteus muscles. The 
facial and abdominal muscle tone reduced. Beevor’s sign was positive. 
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Deep tendon reflexes, sensation, coordination and cognitive functions 
were normal. There was no hearing loss or clear visual loss. Scoliosis was 
not apparent (Fig. 1d). 
Needle electromyography (nEMG) displayed myopathic changes 
with polyphasic potentials, especially in proximal muscles. Muscle CT 
revealed marked muscle atrophy in the thorax, abdomen, paravertebral 
muscles, left upper arm, right hamstrings, and left lower leg (Fig. 1 a–c). 
A muscle biopsy from the patient’s right biceps brachii revealed 
myopathic changes with mild to moderate variation in fiber size and 
remarkable adipose tissue infiltration. Genetic testing revealed that the 
patient carried a D4Z4 reduced allele with three repeats. A chest X-ray 
showed an enlarged cardiac outline with cardiothoracic ratio (CTR) of 
60% without apparent pulmonary opacity. The electrocardiogram (ECG) 
showed regular sinus rhythm with findings of left ventricular hyper-
trophy. The pulmonary function test showed a declined forced vital 
capacity (FVC) of 1.16 L (33.9% predicted) and a preserved FEV1/FVC 
of 0.86 (0.83 L/1.16 L). Serum creatine phosphokinase (CPK) was 
Fig. 1. a. Muscle CT scan axial images of the thorax (upper), abdomen (lower). Note severe muscle atrophy in the thorax, left abdomen, paravertebral muscles 
asymmetrical muscle atrophy in the thighs and lower legs. b. Muscle CT scan coronal image of the thorax, abdomen. Note elevation of the right diaphragm. c. Muscle 
CT scan axial images of the thighs (asterisk) and the lower legs (doble asterisks). Note sever muscle atrophy in the right hamstring and left lower leg. d. CT scan of the 
vertebral column. Scoliosis is not obviously observed. 
Table 1 
Blood test results.  
CBC Biochemical tests ABG 
WBC 7300 /μL AST 43 IU/L pH 7.423 
RBC 476*104/μL ALT 86 IU/L pO2 81.8 mmHg 
Hb 14.7 g/dL γGTP 54 IU/L pCO2 52.2 mmHg 
Plt. 28.8*104/μL LDH 236 IU/L HCO3− 33.4 mEq/L   
CPK 145 IU/mL B.E. 7.7   
BUN 15.0 mg/dL SaO2 92%   
Cr 0.61 mg/dL     
UA 4.7 mg/dL     
Na 145 mEq/L     
K 4.0 mEq/L     
Cl 105 mEq/L     
BS 118 mg/dL   
CBC: complete blood count; ABG: arterial blood gas 
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145 IU/mL. Other blood tests were largely normal (Table 1, left and 
middle lines). Room air arterial blood gas showed elevated partial 
pressure of carbon dioxide (PaCO2 52.2 mmHg) (Table 1, right line). The 
electrocardiogram showed regular sinus rhythm with findings of left 
ventricular (LV) hypertrophy. The ultrasonic echocardiogram (UCG) 
showed diffuse LV hypokinesis, ventricular septum thickening, peri-
cardial effusion, and decreased LV ejection fraction (LVDd 57 mm, LVDs 
49 mm, LVEF 30%). UCG showed normal right ventricular diameter of 
29 mm. 
After admission, continuous intravenous infusion of furosemide and 
carperitide, and oxygen administration, improved CHF. Non-invasive 
positive pressure ventilation (NPPV) was recommended, but was not 
accepted by the patient. 
2. Discussion 
We examined a case of FSHD with slowly progressive muscle 
weakness for approximately 40 years with severe RVD and CHF. 
Symptoms of respiratory involvement began around the age of 40, and 
emergency treatment was required for exacerbation of CHF after the age 
of 50. 
RVD was generally defined as an FEV1/FVC >0.70 and an FVC 
<80% predicted. In the present case, the result of pulmonary function 
test corresponded to RVD. Previous studies reported that respiratory 
involvement occurs in 1.25% to 9.6% of patients with FSHD [4,5]. 
However, a recent report suggested that approximately 40% of FSHD 
patients exhibited reduced respiratory function with a predominantly 
restrictive pattern [2]. Patients with neuromuscular-related RVD 
generally have no subjective symptoms. Therefore, it is recommended to 
obtain baseline pulmonary function tests from all patients with FSHD. 
Previous electrocardiographic studies reported that approximately 
50% of patients experienced cardiac anomalies and the most frequent 
cardiac complication was incomplete right bundle branch block (iRBBB) 
(25%) [3]. However, UCG studies in FSHD patients suggest that struc-
tural abnormalities, including heart failure or LV dysfunction, are 
extremely rare [6,7]. The only case we identified was a 38-year-old 
FSHD patient with biopsy-proven cardiomyopathy, reported by Tsuji 
et al. [8]. In the present case, despite the subjective symptoms, the pa-
tient had no opportunity to check for respiratory or cardiac function, 
and finally required urgent hospitalization for CHF. He had several 
cardiovascular risks, such as hypertension, obesity, and sleep apnea, 
therefore it must be considered that his heart failure may be caused by 
factors other than FSHD. Although cardiac dysfunction other than 
arrhythmia is rare, patient should be evaluated for cardiac function if 
they develop apparent signs or symptoms of cardiac dysfunction in 
FSHD. 
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